X

Clinical Trials

Contact Us

EA5162 (suspended effective 7/9/19)

Study Number: EA5162 (suspended effective 7/9/19)

This phase II trial studies how well osimertinib works in treating patients with non-small cell lung cancer with EGFR exon 20 insertion mutation that is stage IIIB-IV or has come back. Osimertinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.

Please Note:

Because of the rarity of this disease type, this is a "just in time" study. This means that once a patient is identified and the CRA is informed, it will go through the regulatory process and may take up to 10 days to be approved for use.

Contact Person(s)
  • Laura O’Brien, 314-996-5868

View More Information - This link will take you to clinicaltrials.gov for specific study information including eligibility criteria. A full list of participating institutions can also be found on this page.